Literature DB >> 30241668

Risk of Coronary Artery Disease in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis.

Huimin Li1, Qian Tong1, Lirong Guo1, Shui Yu1, Yuewei Li1, Qinqin Cao1, Jinwei Li1, Feng Li2.   

Abstract

BACKGROUND: The association between chronic inflammation and the accelerated development of atherosclerosis is well recognized. However, it remains controversial as to whether the risk of coronary artery disease (CAD) is elevated in patients with systemic lupus erythematosus (SLE). The objective of this meta-analysis was to obtain a better estimate of the risk of CAD in patients with SLE.
METHODS: An English-restricted literature review was conducted according to PRISMA guidelines using key databases, surveying all articles published through October 31, 2017. Specific search terms included "SLE" and "coronary artery disease" as well as appropriate MeSH terms. The Newcastle-Ottawa scale was used for quality assessment.
RESULTS: Nine studies were identified and included in this meta-analysis. The pooled risk ratio of CAD in patients with SLE was 3.39 (95% CI: 2.15-5.35). The statistical heterogeneity of this meta-analysis was high, with an I2 value of 79.5%. An elevated risk of CAD was consistently observed in both female and male SLE patients (pooled risk ratio: 3.27 [95% CI: 2.01-5.30] and 3.16 [95% CI: 2.02-4.94], respectively).
CONCLUSIONS: SLE patients are at significantly higher risk of developing CAD. However, as relatively few studies were available for incorporation into this meta-analysis, there is a clear need for further studies with larger sample sizes that better parse gender-related differences in CAD susceptibility among SLE patients. Future work to standardize cardiovascular risk factor identification and monitoring in SLE patients is also needed.
Copyright © 2018 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Lupus erythematosus disseminates; Systemic lupus erythematosus

Mesh:

Year:  2018        PMID: 30241668     DOI: 10.1016/j.amjms.2018.08.001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

Review 1.  Spontaneous coronary artery dissection in systemic lupus erythematosus: case-based review.

Authors:  Bonifacio Álvarez-Lario; Laura Álvarez-Roy; Sandra Mayordomo-Gómez; Juan Marcos García-García
Journal:  Rheumatol Int       Date:  2019-06-21       Impact factor: 2.631

2.  Time-Dependent Risk of Acute Myocardial Infarction in Patients With Alopecia Areata in Korea.

Authors:  Jung-Won Shin; Taeuk Kang; Ji Sung Lee; Min Ji Kang; Chang-Hun Huh; Min-Su Kim; Hyun Jung Kim; Hyeong Sik Ahn
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

Review 3.  Innate Immune Dysregulation in the Development of Cardiovascular Disease in Lupus.

Authors:  Gantsetseg Tumurkhuu; Erica Montano; Caroline Jefferies
Journal:  Curr Rheumatol Rep       Date:  2019-07-23       Impact factor: 4.592

Review 4.  The evolving role of coronary computed tomography in understanding sex differences in coronary atherosclerosis.

Authors:  Keva Garg; Toral R Patel; Arjun Kanwal; Todd C Villines; Niti R Aggarwal; Khurram Nasir; Roger S Blumenthal; Michael J Blaha; Pamela S Douglas; Leslee J Shaw; Garima Sharma
Journal:  J Cardiovasc Comput Tomogr       Date:  2021-10-08

5.  Inflammation and autoimmunity in atherosclerosis.

Authors:  Stanislaw Surma; Krzysztof J Filipiak
Journal:  Reumatologia       Date:  2022-02-28

Review 6.  Disorders of the Aorta and Aortic Valve in Connective Tissue Diseases.

Authors:  Bogna Grygiel-Górniak; Mary-Tiffany Oduah; Abdulbaril Olagunju; Michal Klokner
Journal:  Curr Cardiol Rep       Date:  2020-06-19       Impact factor: 2.931

7.  Coronary Heart Disease and Cardiovascular Risk Factors in Patients With Idiopathic Inflammatory Myopathies: A Systemic Review and Meta-Analysis.

Authors:  Li Qin; Fang Li; Qiang Luo; Lifang Chen; Xiaoqian Yang; Han Wang
Journal:  Front Med (Lausanne)       Date:  2022-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.